NanoViricides (NYSE-A:NNVC) announced that it will be presenting at the Biotech Showcase 2024 in San Francisco on Tuesday, January 9, at 3.30pm Pacific Time.
CEO Anil Diwan will provide an update on the company's successful Phase 1 clinical trials of NV-CoV-2 oral syrup and oral gummies drug products that contain the novel ultra-broad-spectrum antiviral nanomachine active ingredient NV-387.
Registered attendees can watch the company’s presentation live and access a recorded version after the event.